Irina Studneva

Irina Studneva

Auto-generated profile, based on publicly available information

Irina Studneva

National Medical Research Center for Cardiology, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPMarina Palkeeva
Marina Palkeeva
ISIrina Studneva
Irina Studneva
AMAlexander Molokoedov
Alexander Molokoedov
LSLarisa Serebryakova
Larisa Serebryakova
OVOksana Veselova
Oksana Veselova
OPOleg Pisarenko
Oleg Pisarenko
N-terminal fragments of galanin (2-11) and (2-15) are critical for binding to GalR1-3 receptors, members of the G-protein-coupled receptor superfamily, and are involved in myocardial protection against ischemia/reperfusion (I/R) injury. This study was designed to synthesize novel GalR1-3 agonists with improved properties and evaluate their efficiency as cardioprotective agents. Peptide agonists were synthesized by the automatic solid phase method using Fmoc technology and purified by preparative HPLC. Their chemical structure was identified by 1H-NMR spectroscopy and MALDI-TOF mass spectrometry. Novel ligands of galanin receptors have greater solubility in water than natural galanin fragments. Cardiac function indices, myocardial infarct size and plasma activity of creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) were measured to assess the peptide bioactivity. Infusion of optimal concentrations of the peptides (210-240 μM) after global ischemia enhanced functional recovery of isolated rat heart during reperfusion. Intravenous administration of the peptides in a dose range of 1-2 mg/kg at the onset of reperfusion significantly reduced infarct size and plasma levels of CK-MB and LDH in rats in vivo. The chimeric ligand [βAla14, His15]-galanin (2-15) exhibited the most beneficial effect on both models of I/R injury. The results suggest that pharmacological agonists of GalR1-3 receptors can be a rational basis for drug developments in the field of cardiovascular diseases.

20 September 2018 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
ISIrina Studneva
Irina Studneva
MPMarina Palkeeva
Marina Palkeeva
OVOksana Veselova
Oksana Veselova
AMAlexander Molokoedov
Alexander Molokoedov
MOMichael Ovchinnikov
Michael Ovchinnikov
OPOleg Pisarenko
Oleg Pisarenko

16 April 2020 in Acta Naturae
Verified
Journal Article
Open access
PDF file
ISIrina M. Studneva
Irina M. Studneva
OVOksana Veselova
Oksana Veselova
ABArthur A. Bahtin
Arthur A. Bahtin
GKGalina G. Konovalova
Galina G. Konovalova
VLVadim Z. Lankin
Vadim Z. Lankin
OPOleg Pisarenko
Oleg Pisarenko
The use of the anticancer drug doxorubicin (Dox) is limited by its cardiotoxic effect. The aim of this work was to study the effect of a new synthetic agonist of the galanin receptor GalR1-3 [Ala14, His15]-galanine (215) (G) on the metabolism, antioxidant enzyme activity, and cardiac function in rats with cardiomyopathy (CM) caused by chronic administration of Dox. Coadministration of peptide G and Dox significantly increased the fractional shortening (FS) and ejection fraction (EF) by an average of 30 4% compared with the indices in the Dox group. The reduced severity of cardiac dysfunction under the action of G was accompanied by a 2.5-fold decrease in the activity of creatine kinase-MB (CK-MB) in blood plasma. The protective mechanism of the action of peptide G is caused by a reduced lipid peroxidation (LP) that is due to the increased activity of Cu,Zn superoxide dismutase (Cu,Zn-SOD) and glutathione peroxidase (GSH-Px) in the damaged heart. Administration of peptide G significantly increased the adenine nucleotide pool (AH), ATP content, and the levels of phosphocreatine (PCr) and total creatine (Cr) in the damaged myocardium. It also reduced lactate accumulation relative to its content in the Dox group. The better energy supply of cardiomyocytes after treatment with peptide G prevented the accumulation of cytotoxic ammonia and disruption in the metabolism of the key myocardial amino acids (glutamic acid (Glu), aspartic acid (Asp), and alanine (Ala)). Peptide G significantly improved the morphological parameters of the heart in rats treated with Dox. The results show promise in using peptide G to efficiently correct functional, morphological, and metabolic damage to the heart caused by anthracycline chemotherapy.

1 January 2019 in Peptides
Verified
Journal Article
Closed access
LSLarisa Serebryakova
Larisa Serebryakova
MPMarina Palkeeva
Marina Palkeeva
ISIrina Studneva
Irina Studneva
AMAlexander Molokoedov
Alexander Molokoedov
OVOksana Veselova
Oksana Veselova
OPOleg Pisarenko
Oleg Pisarenko

1 July 2020 in Peptides
Verified
Journal Article
Closed access
MSMaria Sidorova
Maria Sidorova
ISIrina Studneva
Irina Studneva
VBValery Bushuev
Valery Bushuev
MPMarina Palkeeva
Marina Palkeeva
AMAlexander Molokoedov
Alexander Molokoedov
OPOleg Pisarenko
Oleg Pisarenko

1 January 2021 in Journal of Surgical Research
Verified
Journal Article
Closed access
OPOleg Pisarenko
Oleg Pisarenko
ISIrina Studneva
Irina Studneva